Contribute Try STAT+ Today

During 2019, drug makers raised prices on seven widely used medicines by substantial amounts without any new clinical evidence to justify the increases, leading patients and insurers in the U.S. to spend an added $1.2 billion that year, according to a new analysis.

For instance, Salix Pharmaceuticals raised the price on Xifaxan, its irritable bowel disease treatment, by 13%, after accounting for rebates, discounts and other fees, which led to an extra $173 million in spending had the company not raised the price. And Amgen (AMGN) boosted the price of its Enbrel medicine for rheumatoid arthritis and other ailments by 8.9%, after rebates and fees, which cost the U.S. health care system an extra $403 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ed, You get it !! It’s very simple, as you know PCMA defines drug rebates as “a tool for proper placement on drug formularies.”
    The larger the “drug Rebate” the higher tier the drug will be on the drug formulary. This is pure extortion by the PBM’s to have
    a Mfg’s drug to be covered on a patient’s drug plan. If the drug is not on formulary it’s very unlikely the patient will pay for it.
    The PBM’s know that and are taking advantage of that fact. The solution is simple, GET RID OF THE PBM’s !!!!
    We’ll all save billion’s of dollars!!

Comments are closed.